ArticlemSystems2019
Natural Products and Synthetic Biology: Where We Are and Where We Need To Go.
Article in mSystems, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Computational investigation for exploring botanical ingredients as potential negative allosteric modulators targeting metabotropic glutamate receptor 5.Research in pharmaceutical sciences · 2026Article
- Discovery of novel InhA inhibitors through structural bioinformatics and machine learning-driven QSAR screening of natural products.Biology methods & protocols · 2026Article
- Natural Product-Derived Drugs: Structural Insights into Their Biological Mechanisms.Biomolecules · 2025Review
- A review of natural products as a source of next-generation drugs against apicomplexan parasites.npj antimicrobials and resistance · 2025Review
- Metagenomic domain substitution for the high-throughput modification of nonribosomal peptides.Nature chemical biology · 2024Article
- Global characterization of biosynthetic gene clusters in non-model eukaryotes using domain architectures.Scientific reports · 2024Article
- Review
- Characterization of cross-species transcription and splicing from Penicillium to Saccharomyces cerevisiae.Journal of industrial microbiology & biotechnology · 2021Article
- Article
- The need to innovate sample collection and library generation in microbial drug discovery: a focus on academia.Natural product reports · 2021Article
- Metagenomic Exploration of the Marine SpongemBio · 2020Article
- Heterologous Production of Lasso Peptide Capistruin in aACS synthetic biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The biosynthetic talent of microorganisms has been harnessed for drug discovery for almost a century. Microbial metabolites not only account for the majority of antibiotics available today, but have also led to anticancer, immunosuppressant, and cholesterol-lowering drugs. Yet, inherent challenges of natural products-including inadequate supply and difficulties with structure diversification-contributed to their deprioritization as a source of pharmaceuticals. In recent years, advances in genome sequencing and synthetic biology spurred a renewed interest in natural products. Bacterial genomes encode an abundance of natural products awaiting discovery. Synthetic biology can facilitate not only discovery and improvements in supply, but also structure diversification. This perspective highlights prior accomplishments in the field of synthetic biology and natural products by the scientific community at large, including research from our laboratory. We also provide our opinion as to where we need to go to continue advancing the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.